Articles related to CLINICAL STUDY

Unraveling Patient Perspectives on DOAC Safety: Key Findings and Implications for Healthcare Practice A recent study that delves into the complex interactions of direct oral anticoagulants (DOACs) usage offers insightful information about patient experiences and suggests ways to increase patients’ safety and adherence.

Understanding the Effects of Drugs with Depressive Symptom Side Effects on Patients with MDD Learn more about the complex interaction between the usage of specific drugs and the severity of depressive symptoms in people with major depressive disorder (MDD).

Dopaminergic Dysfunction: A Key Player in Parkinson’s Disease Motivational Symptoms This study reveals a significant link between dopaminergic dysfunction and the emergence of motivational symptoms in Parkinson’s disease. Striatal DAT imaging emerges as a potential tool for predicting apathy/anhedonia risk, opening new avenues for intervention strategies.

Evaluating the Timing of DOAC Initiation Post-Stroke: Key Findings Here are the key findings from a recent multi-country, open-label research that explores the best time to start direct oral anticoagulants (DOACs) in atrial fibrillation patients after a stroke.

Decoding the Efficacy: Ketamine and ECT in the Battle Against Treatment-Resistant Depression As you delve into the comparative effectiveness of ketamine and ECT, NEJM highlights the key findings from a recent noninferiority trial that could reshape your understanding of these treatments.

Investigating how an insulin bolus affects the management of diabetic ketoacidosis reveals startling new information. In the diabetes field, experts widely use insulin as a core treatment for diabetic ketoacidosis (DKA). However, the debate over the best dosage and method of administration, specifically concerning the use of an initial insulin bolus, continues. This study evaluates the safety and effectiveness of this insulin bolus in DKA treatment. Employing a retrospective chart review, researchers examined patient outcomes for DKA treatment with and without an insulin bolus. They included 59 patients in the bolus group, and 108 in the non-bolus group. The study primarily tracked whether the administration of insulin had to be interrupted, or if patients experienced hypoglycemia or hypokalemia within eight hours of starting insulin. Comparing baseline characteristics, the groups showed no significant differences. Most patients exhibited mild DKA. Results revealed that adverse effects—particularly hypokalemia—occurred significantly more often in the bolus group (45.8% versus 25%, P = .003). Additionally, while time to anion gap closure was shorter in the bolus group, this did not reach statistical significance (6:39 versus 9:00, P = .063). Similarly, non-significant differences emerged in time to discontinuation of insulin infusion and time to ICU and hospital discharge. […]